Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 17/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500895 | 0.78 | MAPK9 (0.58) | MAPK9MAPK10L3MBTL1 | |
| SCHEMBL12141042 | 0.74 | ALDH1A1 (0.48) | S1PR3S1PR1S1PR4S1PR2L3MBTL1 | |
| SCHEMBL8307228 | 0.73 | MAPK9 (0.50) | MAPK9MAPK10L3MBTL1 | |
| SCHEMBL5622301 | 0.71 | MAPK9 (0.51) | MAPK9MAPK10L3MBTL1 | |
| SCHEMBL15612596 | 0.66 | S1PR3 (0.34) | S1PR3S1PR1S1PR4S1PR2 | |
| SCHEMBL20209121 | 0.66 | ADRA2A (0.35) | S1PR3S1PR1S1PR4S1PR2 | |
| SCHEMBL15612244 | 0.66 | S1PR3 (0.36) | S1PR3S1PR1S1PR4S1PR2 | |
| SCHEMBL1519025 | 0.65 | MAPK10 (1.00) | MAPK9MAPK10 | |
| SCHEMBL24350064 | 0.63 | MAPK9 (0.43) | MAPK9MAPK10S1PR2L3MBTL1 | |
| SCHEMBL13316533 | 0.63 | GBA1 (0.40) | S1PR3S1PR1S1PR4S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855212-B2 | Pyridinyl acetonitriles | MERCK SERONO SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7855212-B2 | Pyridinyl acetonitriles | MERCK SERONO SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | disclosed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | disclosed |
| WO-2004098607-A1 | PYRIDINYL ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N. V. (AN) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060594-A1 | Pyridinyl acetonitriles | GSK3B, GSK3A, MAPK3 | MAPK9 105/4885MAPK10 86/4885S1PR3 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.